The human placenta performs numerous functions during its limited lifespan and its survival is a necessary prerequisite for fetal nutrition, even in unfavourable conditions. BCL-2 is a proto-oncogene implicated in the regulation of cell death and survival without affecting cell proliferation. An extracellular matrix molecule involved in the reparative and degenerative processes in the human placenta is fibrin. We have analysed by immunohistochemistry the expression of BCL-2 and correlated it with fibrin deposits in placental tissues. In first and third trimester placentas BCL-2 was expressed in the syncytiotrophoblast. Only a few mesenchymal villi (first trimester) or terminal villi (third trimester) showed no staining in the syncytiotrophoblast. Villous cytotrophoblast, mesenchymal cells of the villous cores and extravillous cytotrophoblast of cell columns and cell islands were all negative for BCL-2. BCL-2 expression was enhanced in the syncytiotrophoblast overlying subtrophoblastic fibrin deposits. However, discontinuities and/or variations in intensity of BCL-2 expression characterized not only the villi showing perivillous fibrinoid but also those villi with a massive presence of fibrinoid in their cores. These data suggest that BCL-2 may be necessary for the preservation of the placenta during gestation as well as for the reparative processes of the trophoblast.
Introduction
In multicellular organisms cell number is regulated by the balance between proliferation, growth arrest and apoptosis (Chandler et al., 1994; Hoffman and Liebermann, 1994; Krajewski et al., 1994) . Apoptosis plays an important role in normal tissue homeostasis, where it helps to maintain appropriate cell numbers by ensuring that cell production resulting from cell division is offset by a commensurate amount of cell loss (Krajewski et al., 1996) . Among the regulators of apoptosis, members of the BCL-2 gene family stand out since their expression modulates cell death (Lu et al., 1996) . Genes of this family can be divided into two functionally antagonist groups: (i) cell death suppressors such as BCL-2, BCL-X L and MCL; and (ii) cell death promoters such as BAX, BCL-X S , BAK and BAD (Krajewski et al., 1996) . Recently, several studies have shown that BCL-2 and BAX may be regulated by p53 (Kernohan and Cox, 1996) . High levels of BCL-2 protein favour cell survival, while high levels of wild-type p53 lead to an increase in BAX and a decrease in BCL-2 (Kernohan and Cox, 1996) . The BCL-2 proto-oncogene codes for a protein localized mainly in the mitochondrial membrane, but also found in the nuclear membrane. It is a membrane-associated protein containing a hydrophobic carboxyl terminus that may locate it to intracellular membranes, leaving the remainder of the protein in the cytosol (Lu et al., 1996) . The putative role of the BCL-2 protein is to extend cell survival by protecting the cell against apoptosis without affecting cell proliferation (Harmsel et al., 1996; McLaren et al., 1997) . Rescue of cells from apoptosis by BCL-2 can occur at any stage of the cell cycle, but the mechanism through which BCL-2 inhibits apoptosis is unclear (Lu et al., 1996) . Moreover, there is increasing evidence that the role of BCL-2 in regulating cell death and survival is also important in differentiation and morphogenesis.
The human placenta is a rapidly developing organ characterized by different types of villi formed throughout gestation (Castellucci et al., 1990) . Placental functions are also performed in various unfavourable gestational conditions, e.g. pre-eclampsia and diabetes, but mechanisms fundamental for placental life and survival in normal and pathological conditions are not fully elucidated. There is a large body of evidence that the extracellular matrix plays an important role in differentiative and in cell survival processes (Meredith et al., 1993; Frisch and Francis, 1994; Zang et al., 1995; Aharoni et al., 1996) . Fibrinoid is a complex of extracellular matrix molecules and it is related to placental morphogenesis (Nelson et al., 1990; Kaufmann et al., 1996; Nelson, 1996) . There are two different types of placental fibrinoid, fibrin-type fibrinoid and matrix type-fibrinoid (Frank et al., 1994; Kaufmann et al., 1996) . The former is formed mainly from fibrin, is devoid of viable cells and usually localized in and around the chorionic villi. Matrix type fibrinoid is a secretory product of extravillous trophoblast cells which are embedded in this extracellular matrix.
Two localizations of fibrin-type fibrinoid in the chorionic villi have been previously described: perivillous and intravillous fibrin-type fibrinoids (Wilkin, 1965; Boyd and Hamilton, 1970; Toth et al., 1973; Castellucci et al., 1991; . Fibrin-type fibrinoid is localized mainly in the chorionic villi and fibrin has been shown to play an important role in villous reparative and/or degenerative processes (Nelson et al., 1990; Kaufmann et al., 1996) . In the present study we have investigated the expression of BCL-2 and fibrin in first and third trimester placentas. Because no data are available on possible correlations between fibrin and BCL-2 expression (see also Nelson, 1996) we paid particular attention to possible relationships between these two different molecules and their involvement in development and differentiation. Preliminary data have previously been reported in abstract form .
Materials and methods

Materials
Twenty-five human placentas aged 7 (n ϭ 2), 9 (n ϭ 3), 12 (n ϭ 5), 38 (n ϭ 7), 40 (n ϭ 7) and 43 (n ϭ 1) weeks post menstruation were collected from clinically normal pregnancies interrupted by curettage, for psychosocial or medical reasons which were unlikely to affect placental structure and function, or terminated by Caesarean sections and normal vaginal deliveries.
Tissue preparation for immunohistochemistry
Placentas (first trimester and term) were cut into small blocks. Some tissue blocks were embedded in Tissue-Tek OCT compound ® (Miles Scientific, Naperville, IL, USA) and snap-frozen in liquid nitrogen. Cryostat serial sections (5 µm) were cut at -21°C, mounted on glass slides, fixed for 10 min in cold absolute acetone (4°C), air dried and stored at 4°C until use (up to 1 night from sectioning).
Other tissue blocks were fixed for 1 h at 4°C in Bouin's fixative or in 4% buffered formalin and routinely processed for paraffin embedding at 56°C as previously described . Paraffin serial sections (5 µm) were cut and stretched at 45°C, allowed to dry, and stored at 4°C until use.
Immunohistochemistry
Frozen and paraffin sections from first trimester and term placentas were used. Frozen sections were processed without pre-treatment. Paraffin sections were deparaffinized and rehydrated via xylene and a graded series of ethyl alcohol. Sections were then incubated for 10 min with 0.6% hydrogen peroxide in methanol to inhibit endogenous peroxidases. Frozen and paraffin sections were incubated for 20 min at room temperature with non-immune rabbit serum.
Afterwards the sections were incubated overnight at 4°C with one of the following primary antibodies: (i) a mouse monoclonal antibody Pezzella et al., 1990 ) diluted 1:80; (ii) a mouse monoclonal antibody recognizing the human BCL-2 oncoprotein diluted 1:50 (Dako, Glostrup, Denmark); (iii) a mouse monoclonal antibody that binds to fibrin but not to fibrinogen, diluted 1:100 (Immunotech SA, Marseille, France). After washing with phosphate-buffered saline (PBS) the bound antibody was visualized by the peroxidase ABC method (Hsu and Raine, 1981) using diaminobenzidine (Sigma Chemical Co., St Louis, MO, USA) as developer. The sections were rinsed with distilled water and mounted in an aqueous mounting solution. Some of the sections were not counterstained with Mayer's haematoxylin. For the above immunohistochemical procedures controls were performed replacing the primary antibody by 10% non-immune serum or by PBS. Further controls were performed omitting the secondary antibody. Controls were always negative.
Results
Results were qualitatively identical using paraffin or frozen sections as well as with the two different antibodies against BCL-2. Therefore no separate descriptions will be provided.
Chorionic villi
BCL-2 expression was present in the syncytiotrophoblast of all the placentas analysed in this study. Villous cytotrophoblast as well as the various cellular components of the stroma of the different types of villi were always negative (Figures 1  and 2 ). Serial sections of normal placentas were studied in order to see if fibrin deposition could be related to alterations of BCL-2 expression. Villi showing intravillous and/or perivillous fibrin deposits were analysed in more detail. Where fibrin deposits were mainly underlying the trophoblast, i.e. subtrophoblastic, the expression of BCL-2 was strongly enhanced in the overlying corresponding area of syncytium (Figures 3-6) . Villi characterized by a massive presence of fibrinoid in their entire villous core showed a variable intensity of BCL-2 immunostaining in the profiles of syncytiotrophoblast still covering the villus. In those villi showing perivillous fibrin BCL-2 was not expressed in those areas where the syncytiotrophoblast was largely damaged or absent (syncytiotrophoblastic breaches) due to degenerative processes (Figures 3 and 4) .
In very few villi the syncytiotrophoblast was unstained or hardly stained for BCL-2 (Figures 7 and 8 ) in first and third trimester placentas. Such villi did not show pathological alterations at the light microscopic level, and they were of the mesenchymal type (in the first trimester) or belonged to the terminal villous type (at the end of gestation). Serial sections (up to 150 µm) of these negative villi showed no immunostaining for BCL-2 nor for fibrin in such villi. These villi were rare: we observed a maximum of three of such villi per paraffin section. cells deep in the uteroplacental junctional zone were positive for BCL-2 (Figure 9 ).
Discussion
The syncytiotrophoblast is a terminally differentiated nonproliferating fetal epithelium which constitutes a permanent continuous surface barrier directly in contact with maternal cells. The expression of BCL-2 in the syncytiotrophoblast could be a fundamental mechanism by which this important epithelial component of the placenta is preserved. Indeed, it has to maintain its main functions such as an immunological barrier, maternal/fetal transport and hormone production for 9 months (Sakuragi et al., 1994; Lea et al., 1997) . Interestingly, in some other organs and tissues BCL-2 is topographically restricted to long-life progenitor cells (Hockenbery et al., 1991; De Franco, 1992) . For instance, in most epithelial tissues the major groups of cells which express BCL-2 are the proliferating stem cells such as basal keratinocytes and cells at the base of intestinal crypts (Lu et al., 1996) . Therefore, our data on the positivity of the syncytiotrophoblast for BCL-2 are of great interest because they prove that the relationship between BCL-2 expression and cell proliferation does not appear to be exclusive. This is in agreement with the data of Hockenbery et al. (1991) and De Franco (1992) who have shown that only the mature, highly differentiated thymocytes of the medulla are strongly BCL-2 stained. Moreover, the observations of Lu and coworkers (1993) about the endometrium and mammary ducts suggest that BCL-2 appears to be expressed in a selected group of highly differentiated cells responsive to hormonal stimulation. BCL-2 expression in the syncytiotrophoblast did not show decrease in immunostaining at the end of gestation, not even in the 43 week placenta. Thus, BCL-2 is involved in the preservation of the syncytiotrophoblast until delivery even if this occurs in very late stages of pregnancy such as week 43.
Serial sections were useful for evaluating BCL-2 immunostaining in chorionic villi where fibrin deposits were present due to degenerative/reparative processes. Interestingly, our study shows for the first time that subtrophoblastic fibrin deposits are frequently related to enhanced expression of BCL-2 in the overlying syncytiotrophoblast. These data can explain at least in part previous observations suggesting that fibrintype fibrinoid is not an indicator of villous degeneration and that the syncytium overlying small intravillous fibrinoid deposits degenerates only secondarily if at all (Boyd and Hamilton, 1970; Fox 1975; Kaufmann et al., 1996) . Several studies have emphasized the possibility that the subtrophoblastic intravillous fibrinoid is the result of immunological processes altering the syncytiotrophoblastic barrier (Gille et al., 1974 ; for a review see Kaufmann et al., 1996) . In response to such alterations we can have the formation of subtrophoblastic intravillous fibrinoid acting as an immunologically protective barrier or immunoabsorptive sponge (Kaufmann et al., 1996) together with an increase in expression of BCL-2 in the overlying syncytium as demonstrated by our findings. Thus, the overlying syncytium could both avoid degeneration through BCL-2 higher expression and, in the meantime, activate possible repair mechanisms to reconstitute its barrier capacity. Such repair mechanisms have to be realized in a relatively short time and it cannot be excluded that apoptotic and/or necrotic processes in the overlying syncytiotrophoblast can become preponderant if repair does not take place or is unsuccessful. Interestingly, recent studies using different techniques demonstrated apoptotic nuclei in the syncytiotrophoblast associated with fibrin although such nuclei were also found in fibrin free areas of the syncytium (Thiet et al., 1995; Yasuda et al., 1995; Nelson, 1996; M.Castellucci and J.Mühlhauser, unpublished observations) . Thus, to the best of our knowledge syncytiotrophoblast is the only cell type where both BCL-2, BCL-2 enhancement and apoptotic nuclei are contemporarily present in vivo.
BCL-2 was not expressed where a breach or discontinuity of the trophoblastic covering was present, the latter being substituted by perivillous fibrin. Interestingly, however, BCL-2 was not detectable in some mesenchymal and terminal villi. These were negative for fibrin and no pathological alterations were observable. Previous investigations have pointed out that several molecules can be heterogeneously expressed in a homogeneous villus population. For instance, heterogeneity of mesenchymal villi regarding structure, proliferation patterns and expression of tenascin has been previously described (Richart, 1961; Castellucci et al., 1991; Benirschke and Kaufmann, 1995) . One possible explanation for the heterogeneity of molecular expression in a villus population is that development and differentiation of the villi do not occur contemporarily. This interpretation has also been corroborated by topological analysis (Kosanke et al., 1993) and the heterogeneity of molecular expression can signify that some villi are actively growing or differentiating, others may rest or show retarded development and others may undergo regression (Fox, 1978; Castellucci et al., 1990 Castellucci et al., , 1991 Kosanke et al., 1993) . Indeed, morphogenesis of tree-like structures includes loss of some branches (Castellucci et al., 1990; Kosanke et al., 1993) . The absence of BCL-2 expression could be an early signal for a sequence of events leading to villus regression or degeneration. This signal can be generated by the genetic programme of villous tree morphogenesis and/or by alterations in microenvironmental factors as in the intervillous circulation (see Kaufmann et al., 1996) BCL-2 protein was not expressed both in villous and extravillous cytotrophoblastic cells of cell columns and cell islands. Extravillous cytotrophoblastic cells of the cell columns invade the uterine wall, in some cases migrating deeply into the muscular layer of the uterus (Benirschke and Kaufmann, 1995; Mühlhauser et al., 1995) . Consequently these cells can remain in the uterine wall after delivery. It has been established that these invading cells are differentiated and no longer proliferative (Castellucci et al., 1991; Mühlhauser et al., 1993; Benirschke and Kaufmann, 1995; Kaufmann and Castellucci, 1995) . The lack of BCL-2 expression is probably responsible for a limited survival of these cells after delivery. This hypothesis has been recently strengthened by the observations of Uckan and coworkers (1997) who have suggested a role for FAS-L in the apoptosis of extravillous trophoblastic cells during implantation. Moreover, very preliminary data of our group (Marzioni et al., 1997) have shown a positive reaction product for BAX protein in the extravillous cytotrophoblastic cells invading the uterine wall. Thus, FAS-L and BAX immunoreactivities and the lack of BCL-2 expression can play a pivotal role in the limited lifespan of the invasive extravillous cytotrophoblast.
